Last month (May, 2018) I wrote about a new study published in Iran that looked at the "neuroprotective effects" effects of virgin coconut oil for Alzheimer's patients. The title of the study is Virgin coconut oil (VCO) by normalizing NLRP3 inflammasome showed potential neuroprotective effects in Amyloid-β induced toxicity and high-fat diet fed rat and was published in the journal Food and Chemical Toxicology. While we have been publishing reports of coconut oil reversing the symptoms of Alzheimer's Disease and other neurological diseases for several years now, we believe this was the first peer-reviewed study to actually look at some of the mechanisms of how coconut oil benefits Alzheimer's patients. Now, a second peer-reviewed study has been published here in 2018 looking at the mechanisms of how coconut oil positively affects Alzheimer's patients. Published in the journal, Neurochemical Research, researchers in Japan examined the effects of lauric acid, the most predominant medium chain fatty acid found in coconut oil, on activated microglia in mice. Coconut oil is nature's richest source of lauric acid at about 50% of its composition, and human breast milk comes in a distant second at around 6% lauric acid. The title of the study is Lauric Acid Alleviates Neuroinflammatory Responses by Activated Microglia: Involvement of the GPR40-Dependent Pathway.
Because of its lower cost, canola oil is ubiquitous in processed foods intended for the growing "health conscious" market. Now a recently published study is confirming the suspicions of those of us who refuse to use canola oil. Philadelphia Pennsylvania's Temple University conducted an animal study to determine the validity of canola oil's health claims. Their results were published this month, December, 2017, in the journal Scientific Reports. The study was titled “Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer’s disease.” Could canola oil contribute to the onset of Alzheimer’s Disease?
Two years ago we reported that Eli Lilly had a potential blockbuster drug for Alzheimer’s in the third and final phase of FDA trials. If it won approval, it was expected to bring in $7.6 billion in sales by 2024. The results are in, and it’s back to the drawing board for Eli Lilly. The drug showed no statistically significant benefits in halting cognitive decline. In the meantime—clearly intending to approve this new Alzheimer’s drug—the FDA launched an attack against key brain health supplements picamilon and vinpocetine. There was precedent for such a move—the FDA did the same thing to tryptophan before the first SSRI antidepressant drugs came out. It’s a key move in the crony playbook.
A new study has found that taking powerful antipsychotic drugs significantly increases the likelihood of premature death for Alzheimer’s patients. The study looked at 58,000 people diagnosed with Alzheimer’s between 2005 and 2011. Those who were prescribed antipsychotics (usually to control the unruly behavior some Alzheimer’s patients display) had a 60% higher risk of dying than those who didn’t take the drugs. The study confirms current recommendations that antipsychotics be used only for the most difficult cases for a short period of time. As we’ve reported previously, this advice has not been heeded. A 2015 report from the Government Accountability Office found that nearly one third of seniors with dementia who spend more than 100 days in a nursing home were given antipsychotic drugs—despite the fact that the FDA has never approved such drugs to be used for behavioral problems from dementia.
An episode of Dr. Mark Hyman's “Fat Summit” featured the work of Dr. Dale Bredesen, who specializes in researching and clinically applying his research on those afflicted with dementia, including Alzheimer's. Alzheimer's and other forms of dementia are considered "incurable" by modern pharmaceutical dominated mainstream medicine. Fortunately, Dr. Bredesen is a practitioner of functional medicine, which approaches the underlying cause of any disease then focuses on treatments usually involving systems of holistic or alternative medicine instead of pharmaceutical drugs. His research has been ongoing for 27 years to determine what really causes dementia and Alzheimer's disease (AD). It was fun witnessing Dr. Hyman's energetic, fascinating interview of Dr. Bredesen. Some of what was revealed about Alzheimer's was quite surprising, and his research went beyond the lab to confirm his team's findings clinically. They were actually diagnosing root causes and curing the incurable with natural holistic means.
I brought my 88 year old mother out of 7 years of nursing home neglect/abuse on February 14, 2016. I've been studying the effects of coconut oil and Alzheimer's disease. She was taking 4 units Novolog insulin at meals and 10 units Lantas at night. After applying coconut oil all over her body, I noticed her sugars were continuing to lower without insulin shots. The first 2 days, I saturated her skin and added 1 teaspoon in protein shakes. Her sugars went from 300's to 140. My mother is diagnosed with stage 6 Alzheimer's. She is speaking better and I gave her a Bible story book to read me yesterday and she could read it through with exception of a few words. My mother could not do this one week ago or for the last two years. She is remembering people and things that have not been spoken of for years. I can now show her pictures and she can name people, even her children now. I'm thrilled!
In October we told you about a potential new blockbuster drug for Alzheimer’s from drug giant Eli Lilly. Solanezumab is in the third and final phase of FDA drug trials, and if approved, could bring in at least $7.6 billion in sales by 2024 and probably much more. Other drug companies also have “big” Alzheimer’s drugs in the works. Now the FDA has sent warning letters to five supplement companies targeting the supplement picamilon, which may help with Alzheimer’s, anxiety, and general brain health. The FDA’s attack on picamilon appears to be an attempt to give Big Pharma an unobstructed playing field for their Alzheimer’s drug. Write to the FDA and tell them that picamilon is not a synthetic drug at all, and needs to stay on supplement store shelves!
Alzheimer's Disease and other forms of dementia have become increasingly epidemic among our expanding age 65 and over population. As of 2015, there are 5.3 million Americans diagnosed with Alzheimer's. At least a third of them don't know they are afflicted. Dementia and Alzheimer's are worsening epidemics, and the pharmaceutical industry has not provided real hope. One has to go outside of mainstream medicine's pharmacopoeia to slow or reverse dementia and Alzheimer's or other neurodegenerative diseases such as MS and Parkinson's. Health Impact News has been a leader in the Alternative Media documenting cases where coconut oil has brought tremendous results to those suffering from Alzheimer's and dementia, and the research and case studies are found at CoconutOil.com. Another alternative for Alzheimer's is one that still has legal issues in many states - it's cannabis or medical marijuana. It doesn't have to be smoked. There are edible options available. It may seem that using cannabis to reduce Alzheimer's symptoms is counter intuitive. But in addition to many anecdotal successes with cannabis for Alzheimer's and dementia, there has been some serious research.
Health Impact News has been a leader in the alternative media publishing research and testimonials supporting the positive use of coconut oil with people suffering from Alzheimer's disease. These remarkable stories of families seeing dramatic improvement from Alzheimer's and dementia are documented at CoconutOil.com. In many cases, adding several spoonfuls of coconut oil a day to the diet of one suffering from Alzheimer's and dementia has resulted in memories returning, the ability to once again converse with friends and loved ones, etc. (Read the testimonials.) However, pharma-based physicians and groups have largely condemned the use of coconut oil, stating that all the evidence is "anecdotal," lacking peer-reviewed scientific research. Of course coconut oil is a natural food, with virtually no risk or side effects, and funding for research on a natural food is difficult to come by when no product can be patented as a result of the research, such as lucrative pharmaceutical drugs. As we have stated in the past, the lack of scientific research on coconut oil and Alzheimer's should not stop people from trying it. Some are taking notice and beginning to publish studies, however, so the claim that coconut oil improving Alzheimer's lacks scientific support may not be true much longer. A clinical trial in Spain was published this month (December 2015) studying the effects of coconut oil on Alzheimer's, and the results were very promising. Another study in Florida is in process and should be published in 2016.
At the present time, Eli Lilly has a potential blockbuster drug for Alzheimer’s in the third and final phase of FDA trials. Currently called solanezumab, if approved it could bring in $7.6 billion in sales by 2024—and that might be a conservative estimate. This is despite evidence the drug doesn’t work that well, at least in later stages of the disease. But if it can be shown to have some benefit for the early stages, that could be enough to make it a huge moneymaker and turn around Eli Lilly’s earnings. The stock has already risen on the prospect. Biogen also has an Alzheimer’s drug in trials. The drug companies view Alzheimer’s as one of their very best potential markets. Meanwhile, natural therapies are already showing great promise against Alzheimer’s. We covered some of this in an earlier article. Since then, Dale Bredesen, MD, who works at the Center for Alzheimer’s Disease Research at UCLA, has published a paper reporting success with natural therapies in treating nine out of ten patients. The thrust of Bredesen’s thesis is that as powerful as natural therapies are, they are even more powerful when individualized to the patient, an idea which is complete anathema to the drug companies and their allies at the FDA. More importantly, use of natural therapies could undercut potential drug profits. Is this why brain supplements are suddenly under attack? Does the FDA want to clear away competition for the new drug?